Skip to main content

Investors

Welcome to AbolerIS Pharma! Since our inception in 2019, we’ve been dedicated to revolutionizing the pharmaceutical landscape. We are delighted to share that our commitment has led to the successful closure of two rounds of funding, a testament to our vision and the trust of our investors in shaping a healthier future.

Our Investors

Newton Biocapital

Newton Biocapital (NBC) is a hands-on investor focusing on early-stage life sciences companies targeting chronic health conditions. NBC has a presence in Europe/Japan and leverages its expertise to help its portfolio companies focus on the right indication and clinical trial design, thereby helping them to progress successfully through challenging early drug development phases.

Read More

Caixa Capital Risc

Caixa Capital Risc is a venture capital firm that invests in life sciences through its specialized fund Criteria Bio Ventures. Criteria Bio Ventures teams up with driven entrepreneurs to build innovative biotech companies that transform patients’ lives. Criteria Bio Ventures invests in international companies that provide disruptive therapeutic approaches centered on addressing unmet medical needs, with a primary focus on Europe. Caixa Capital Risc is part of the CriteriaCaixa group.

Read More

Sound Bioventures

Sound Bioventures is a therapeutics-focused venture fund, that invests in about-to-be clinical or clinical-stage biotech companies in Europe and the US. Founded by a team of experienced life science investors and operators, the fund invests in companies addressing significant unmet medical needs with potential for a profound impact on human health.

Read More

SFPI-FPIM

The Federal Holding and Investment Company is Belgium’s Sovereign Wealth Fund with about €8.6 billion in assets under management for the Federal State. It supports Belgian companies, including SMEs and scale-ups, by providing smart capital solutions to help them become industry leaders. Additionally, the SFPI-FPIM plays a crucial role in ensuring the long-term stability of the Belgian economy by strategically investing in promising and established companies across various sectors.

Read More

WE Life Sciences

WE Life Sciences invests in Wallonia’s “Local Heroes” – researchers and entrepreneurs leveraging innovation to foster a sustainable and equitable global economy. Emphasizing diversity and cross-fertilization, they support a wide range of health sector companies at various developmental stages and driven by a long-term vision. As a pioneer, premature, and patient investor, WE Life Sciences encourages entrepreneurs to explore new areas, strengthening Wallonia’s economic health.

Read More

Sambrinvest

With 35 years of experience alongside entrepreneurs, more than 270 companies in portfolio and €160M under management, Sambrinvest is a major player in venture capital in the region of Charleroi Métropole, Wallonia, Belgium. More than an investor, Sambrinvest is the catalyst for local ecosystems development, such as Biotech, Digital and Engineering. Thanks to its expertise, it advises entrepreneurs at every development stage of their projects whilst respecting their management autonomy.

Read More

Investsud Tech

Investsud Tech is a specialized VC fund investing in seed and early-stage startups. Its portfolio of companies features some of the leading young technological companies in Wallonia. The fund belongs to the INVESTSUD Group, which is a private equity firm located in Wallonia, Belgium, and dedicated to accompanying small and medium-sized family companies, with equity or quasi-equity funds.

Read More

Relyens Innovation Santé/Turenne Capital

Relyens Innovation Santé, launched in 2014, is a health-focused venture capital vehicle owned by Relyens, a mutual insurance company. Supported by Turenne Santé, the Health Division of Turenne Group, its mission is to aid the growth of innovative health sector companies. Turenne Group, a prominent private equity company in France, manages €1.6 billion in assets and supports 290 business leaders across various sectors, including healthcare.

Turenne GroupRelyens

New Investors

AbolerIS Pharma isn’t just a biotech company; we’re pioneers of medical transformation. Our commitment to advancing healthcare is deeply rooted in groundbreaking science that drives the development of life-changing therapies.

By investing in AbolerIS Pharma, you’re not only ensuring robust returns but also playing a pivotal role in enhancing global health outcomes and making alternative treatments possible for those who suffer from inflammatory, autoimmune, and degenerative diseases.

Why Choose Us

Novel and Unique Therapeutic Approaches to Put Immune System Under Control
Elevate Healthcare Through Cutting-edge Science
Unveil the Untapped Potential of Therapeutics
Global Reach, Healing Patients Worldwide

Invest in AbolerIS Pharma today and build a healthier, brighter future together!

Ann Meulemans

CEO

Contact us